- Category: HIV Treatment
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
Marta Boffito from Chelsea and Westminster Hospital in London presented an overview of some of the challenges and opportunities in the development of long-acting antiretroviral agents for HIV treatment and prevention in a themed discussion at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
Antiretroviral drugs with extended activity that can be taken once weekly or even less often are a fond hope for many people with HIV, and may help improve adherence, according to Boffito. Long-acting agents may be equally important for pre-exposure prophylaxis (PrEP), for which consistent use has proven both crucial and difficult to achieve.
[Marta Boffito speaks with Gregory Fowler about long-acting antiretrovirals, CROI 2013, Atlanta, March 5, 2013]
Marta Boffito. Challenges and Opportunities for the Development of Long-acting ARVs. 20thConference on Retroviruses and Opportunistic Infections (CROI 2013). Atlanta, March 3-6, 2013. Abstract 511.